A Phase 1 b/2 Open-Label Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Colorectal Cancer | NYU Langone Health

Go Back to All Clinical Trials

A Phase 1 b/2 Open-Label Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Colorectal Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Metastatic Colorectal Cancer
Age: Between 18 years - 100 years
Gender: Male or Female

Other Inclusion Criteria:

1) Histologically confirmed metastatic colorectal adenocarcinoma. 2) Must have at least 1 measurable lesion per RECIST v1.1 Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 3) Life expectancy at least 3 months. 4) Adequate hematologic and end-organ function Negative HIV, Hep B and Hep C antibody testing.

You may not be eligible for this study if the following are true:

1) Previous anticancer treatment within 4 weeks prior to initiation of study treatment. 2) Prior allogeneic stem cell or solid organ transplant. 3) Treatment with systemic immunostimulatory agents within 4 weeks prior to initiation of study treatment. 4) Use of any live vaccines against infectious diseases within 28 days of first dose.